

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高视医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

**(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR;
AND
(2) APPOINTMENT OF EXECUTIVE DIRECTOR**

The Board hereby announces that, with effect from August 24, 2023:

1. Mr. Shi Long has resigned as a non-executive Director of the Company; and
2. Ms. Li Wenqi has been appointed as an executive Director of the Company.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Shi Long (“**Mr. Shi**”) has tendered his resignation as a non-executive Director with effect from August 24, 2023 in order to devote more time to focus on his other business commitments.

Mr. Shi has confirmed that he has no disagreement with the Board and there is no other matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude to Mr. Shi for his invaluable contribution and continuous provision of strong support and assistance to the Company during his tenure of office with the Company.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. Li Wenqi (“**Ms. Li**”) has been appointed as an executive Director with effect from August 24, 2023.

Ms. Li Wenqi (李文奇), aged 49, is the chief financial officer and a joint company secretary of the Company. Ms. Li is primarily responsible for the financial management, corporate governance, investor relation and informatization management of the Group. Ms. Li has over 20 years of experience in accounting and financial management. She first joined the Global Vision Corporation* (北京高視遠望科技有限責任公司) in August 1998 and served successively as cashier, accountant, financial supervisor, financial manager and financial controller. She has served as the vice president of the Company from January 2018 to January 2023 and was appointed as a joint company secretary of the Company on November 18, 2021 and the chief financial officer of the Company on January 10, 2023. Ms. Li received her bachelor’s degree in accounting from Beijing Wuzi University (北京物資學院) in the PRC in July 1995. She also obtained accounting specialist qualification conferred by the Ministry of Finance of the PRC in May 1999.

Pursuant to the service contract entered into between the Company and Ms. Li, her initial term of office is three years commencing from August 24, 2023 or until the third annual general meeting of the Company since the date of her appointment, whichever is sooner, and unless terminated by not less than one month’s prior notice in writing served by either party to the other. Ms. Li will hold office until the first annual general meeting of the Company and is eligible for re-election at such meeting, and she will be subject to retirement by rotation and re-election in accordance with the amended and restated memorandum and articles of association of the Company. According to Ms. Li’s service contract, she will receive a total remuneration of RMB800,000 per annum, plus a discretionary management bonus, as recommended by the remuneration committee of the Board and determined by the Board with reference to her role and responsibilities with the Company.

Save as disclosed above and as of the date of this announcement, Ms. Li has confirmed that (i) she is not interested or deemed to be interested in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) she did not hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of her appointment; (iii) she did not have any other relationship with any Director, senior management or substantial shareholders or controlling shareholders of the Company; (iv) she did not hold other positions within the Group; and (v) there is no other information that is required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited nor are there any other matters that need to be brought to the attention of the shareholders of the Company relating to her appointment.

The Board would like to express its warmest welcome to Ms. Li on her appointment.

* *For identification purpose only*

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, August 24, 2023

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.